Sun Pharma recalls 16K bottles of antidepressant tablets in US

By: |
New Delhi | July 27, 2016 9:56 PM

The class III recall is due to 'failed dissolution specifications', the report on the website of United States Food and Drug Administration (USFDA) said.

The buPROPion hydrochloride extended release tablets were manufactured at the company's Halol facility. (Reuters) The buPROPion hydrochloride extended release tablets were manufactured at the company’s Halol facility. (Reuters)

Drug major Sun Pharmaceutical Industries is recalling over 16,000 bottles of an anti-depressant tablets from the US market due to failed dissolution specifications.

The buPROPion hydrochloride extended release tablets were manufactured at the company’s Halol facility.

Sun Pharmaceutical Industries Inc, the company’s US subsidiary, is recalling 16,085 bottles of buPROPion hydrochloride extended release tablets in the strength of 150 mg in a ongoing voluntary nationwide recall, the latest Enforcement Report of the USFDA said.

The class III recall is due to ‘failed dissolution specifications’, the report on the website of United States Food and Drug Administration (USFDA) said.

As per the USFDA a class III recall is initiated in “a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1JSW Steel’s crude steel output jumps to 13.71 LT in April
2COVID crisis: HUL to provide 4,000 oxygen concentrators to India
3Twitter donates USD 15 mn for COVID-19 relief in India